From wheat fields to Washington: a decades-old fear about skies and “sprays” rises again, colliding with science, social media, and the machinery of federal policymaking.
The FDA has unveiled its top science and research priorities for FY 2026 under the GDUFA program, including nitrosamine risk, complex drug development, bioequivalence innovations, and the use of AI and modeling to modernize generics regulation.
Federal judge rules nurse practitioners with doctorates cannot use “doctor/Dr.” in advertising or health care settings likely to make patients think they’re physicians.
Air Force reviews cancer risk in missile crews; early analyses show no excess mortality, but exposures to PCBs and benzene prompt vigilance and targeted histories.